Strategic Acquisition Boston Scientific acquired Valencia Technologies in early 2026, signaling potential scale through expanded distribution and an integrated neuromodulation portfolio. For sales teams, align messaging with Boston Scientific channels, plan for integration timelines, and pursue cross-sell opportunities leveraging the combined footprint.

Reimbursement Advantage Category III CPT code X129T approval, effective January 1, 2024, provides a formal reimbursement path for eCoin procedures, helping clinics bill neuromodulation and driving adoption among practices, hospitals, and ambulatory surgery centers. Develop payer-facing materials and ROI case studies to accelerate uptake.

Clinical Efficiency The eCoin leadless tibial neurostimulator offers 3+ years of relief and can be implanted in a procedure room without general anesthesia, reducing office visits and operating room time. Highlight throughput gains, shorter patient waitlists, and new revenue opportunities for clinics and health systems.

Target Segments Focus sales efforts on high‑volume urology practices, APPs and physicians in outpatient clinics, surgical centers, and hospitals seeking non-surgical UUI management and reduced anesthesia use. Build use cases and clinical briefs that demonstrate rapid patient onboarding and workflow efficiency.

Growth Momentum Recent financing of up to $35 million in 2025 and the appointment of a Vice President of Sales in 2025 indicate a strong growth trajectory. Post acquisition by Boston Scientific, accelerate field hiring, pilot deployments, and strategic partnerships to scale market reach and revenue.